Lead Corporate FP&A Team (4-6 FTEs) supporting Cellular Therapy (CT) focused on placental derived allogeneic Cellular Therapy specializing in Oncology & Immunology and Degenerative Diseases (DD) specializing in Orthopedics, Aesthetics & Ophthalmology. Serve as a key strategic partner to the Executive Leadership Team (ELT) and provide hands on support to all functions (400+ HC) including Commercial, Research, Development, Clinical, Technical Operations and Corporate Functions.• Drive all Corporate Planning cycles including annual Budget, quarterly Forecast Updates and Short-Term Strategic plans• Manage end-to-end enterprise financial support including ad-hoc & monthly ELT and Board of Directors presentations• Support all Commercial Brands and Financial reporting packages across Business Units• Support Portfolio & Program financial management including investment valuation and NPV/eNPV analysis which includes overall market analysis and fully burdened investment cost for internal programs, external collaborations & potential in and/or out licensing opportunities• Manage Total Clinical Study costing including detailed CRO Clinical Budgets and work performed analysis for monthly financial closes and overall program valuation• Proactively identify, design, and implement process and governance improvement to drive enterprise efficiency, top line growth, operational cost savings and resource optimization

Led R&ED Finance Team (5 FTEs) for Capital & Operating results, forecasts, budgets and long-range plans for R&ED teams supporting Hematology, Oncology, Immunology, Inflammation and Neurodegeneration across 8 sites in US & Spain. Managed $800M+ annual Operating spend including early phase clinical trials, $20M Capital spend & supported 900+ HC.• Celgene acquisition by Bristol-Myers Squibb closed in November 2019• Actively supported R&ED finance integration and financial reporting consolidation under new organization structure post acquisition while still under two different ERP systems• Continued to manage 3 - 5 person finance team through integration while providing financial oversight to R&ED divisions for all reporting cycles including Monthly close, Forecast Updates, Long Term Financial Plan and bottoms up Consolidated Budget cycle• Supported heritage Celgene Phase 1 Clinical Studies transition into heritage BMS Portfolio forecasting and reporting process• Led Anaplan Non-Clinical database migration and upgrade to newly redesigned model, system validation & ongoing maintenance across all R&ED divisions• Collaborated closely with HR & Procurement on post acquisition Value Capture Synergy targets, supplier management and rate card optimization across R&ED• Managed overall Academic & Sponsored Research Alliances and BD external partners' collaboration reporting across R&ED

• Managed financial & operating plan for global research and early development (R&ED) organization at a leading biotech company (>$10B Revenue) supporting research, discovery, translational and Early Dev Clinical teams for small & large molecule, biologic and cellular therapy (CAR-T) targets/compounds in therapeutic areas including hematology & oncology, immunology & inflammation and neurodegeneration • Managed 5 person finance team responsible for financial oversight for all R&ED budgets, forecasts, 3 year operating plans and Monthly Close Results• Managed $800M in annual operating expenses, >$100M in Phase 1 Clinical Studies and >$20M in Capital Investments• Worked with Senior Leaders to deliver on long range strategic plan, prepared Executive level reports & presented regularly to R&ED ELT• Supported areas such as Research, Discovery teams per Therapeutic area, Pre-Clinical Development, Early Development Project Leadership, Precision Medicine, Translational Development and Clinical Pharmacology • Supported Early Dev. Clinical Programs from Phase 1 through Proof of Concept including Portfolio Governance Committee, portfolio prioritization, study costing, drug candidate assumptions and other portfolio analytics • Actively engaged in R&ED pre-acquisition reviews and integration efforts with Bristol-Myers Squibb

Provided financial leadership, analytical, operational and strategic support to Oncology Global Technical Research & Development (TRD) and Global Medical Affairs (GMA) functions with $600M annual spend across small molecules, Immuno Oncology & newly acquired ex-GSK Oncology portfolios with 35+ active late stage Phase III compounds. Managed and mentored 1 overseas direct and 1 US indirect report.• Prioritized & consolidated Oncology TRD portfolio by program for internal resources & external project spend for all planning & reporting cycles including monthly outlooks, forecast updates, annual budget planning & 5yr. Strategic Plan• Challenged key programs’ assumptions, strategy, related spend and resource allocation needs by program• Collaborated closely with global Pharma TRD and 8+ internal NVS manufacturing sites • Revamped monthly Global Performance executive presentation to Oncology Finance Management Committee • Worked directly with GSK TRD & GSK Finance leadership team to successfully integrate ex-GSK oncology portfolio• Supported Global Dev. re-organization structure including Baseline calculations, synergy estimates and coordinated revised reporting requirements for new organization structure• Actively supported Global Medical Affairs function and Leadership team with various launch scenarios and incremental funding needs• Key finance partner to Strategic Sourcing to identify, report and exceed annual cost savings targets across the Global R&D Oncology portfolio

Responsible for financial planning, performance monitoring, proposed investment deal analysis and decision support activities for Business Development & Licensing and Inhalation Development. • Key finance resource from initial partner term sheet & contract negotiation process through BD&L assets’ lifecycle• Advised BD&L and Inhalation teams in the evaluation of market opportunities on product acquisitions or development licensing deals and re-evaluation of current portfolio including NPV/IRR analysis and deal structure scenarios • Reviewed accurate deal accounting treatment based on signed contracts and in accordance with IFRS accounting• Actively supported Inhalation R&D Development and clinical portfolio (PK, PD, Device Handling & Clinical studies) and managed annual impairment testing valuations

Finance Lead for US Bio-Pharmaceutical business unit P&L. Utilize financial analysis and business acumen to provide decision support , tactical and/or strategic decisions in a variety of financial and non-financial business areas to deliver on strategic business objectives and financial targets. Work cross-functionally in a worldwide matrix organization.• Analyze Gross to Net adj & Net Sales drivers to limit exposure and optimize sales delivering +72% YOY growth• Evaluate various pricing strategies to increase demand/market share +6%, decrease short dated inventory levels and write off exposure while decreasing overall gross to net sales adjustments by 14% to date• Lead the development, preparation and presentation of management reporting analyses, including performance versus last year, budget and latest forecast, operational KPIs, and annual 5 yr strategic P&L by product line• Prepare global executive business review presentations and actively engage in strategic business discussions to drive commercial brand price/market share, exceed annual financial targets and shape the future for Biosimilars • Support local R&D clinical trials (Phase I & III), device studies and ongoing Phase IV post marketing studies• Lead financial analysis for largest US Biosimilar business development opportunity including business case development (P&L construction, NPV, IRR), contract language review and ongoing Alliance Partner reporting

Led the financial process (monthly financial close, quarterly forecast updates and annual business plan) for US Sales and Gross Profit of $2B for 8 franchises. Managed operating budget of $85M and capital budget of $15M. Managed and mentored six direct reports as well as four external consultants.• Streamlined Sales and Gross Profit forecasting process utilizing Cognos database resulting in less than 1% variance from committed targets• Supported 2 new product launches and customer segmentation initiatives resulting in $15M increased revenue • Revamped monthly Executive Sales Reporting package to Sr. Management reducing preparation time by 50%• Developed financial scorecard for price/volume, market share, customer rank and profit margin analysis • Ensured proper revenue cycle compliance by reviewing and evaluating the monthly Balance Sheet Reserve accounts in accordance with SOX requirements resulting in positive internal and external audit findings• Successfully interacted with Sales force to ensure financial strategy buy-in and resolve customer pricing issues• Created and standardized NPV & IRR financial models for customer pricing proposals and strategic marketing promotions that led to increased revenue, product market share and higher profit margins per Franchise• Performed, reviewed and redesigned input workbooks for Government pricing calculations of Non-Federal Average Manufacturer Price & Average Selling Price in compliance with Federal Supply Schedule sales contract• Built a financial team from one analyst to six person team; selecting, hiring, coaching and mentoring personnel

Led the monthly financial close, quarterly forecast updates and annual business plan for IT and Contracting and two Corporate Regional projects. Managed and mentored three direct reports.• Represented finance on a $200M business case for corporate commercial contracting project and system implementation by partnering with Finance across 23 J&J companies to determine fully loaded cost of contracting to harmonize the contracting process across J&J• Generated comprehensive business case (NPV, IRR) for Data Management Services, a major software system implementation project ($24.8M), which delivered Supply Chain & Contracting function efficiencies• Consolidated and managed $175M Operating Budget chargeout/allocation process and coordinated communication for 23 J&J companies ensuring issue resolution.

Led the monthly financial close, forecast updates and annual budgets for two Global R&D functions, Pre-clinical thru Phase I/IIb, Global Regulatory and local Administration departments with global budget of approx. $450M.• Streamlined and managed Project Portfolio Prioritization process for global Preclinical thru Phase I/IIb studies • Utilized SAP database to provide monthly financial reports to over 21 cost center owners• Acted as the finance lead to business development teams for several in-licensing projects • Led and coordinated merger integration efforts on Chart of Accounts creation and related monthly financial reporting to the newly combined R&D organization

Supported financial cycle for retail properties’ P&L including financial reporting to joint venture partners, lenders, and property managers.• Supported the design and system implementation of an $8.5M financial planning and lease tracking system for all divisions to gain consistency in business processes, ease of data rollout, financial valuation and reporting• Developed annual and 3/5/10 yr. financial projections with related cash flows and NPV analysis enabling enhanced portfolio management prioritization and decision making regarding upcoming acquisitions and disposals

Planned and supervised audit engagements for not-for-profit, private and public companies in multiple industries.• Trained staff accountants improving performance and documentation of audit procedures• Developed and documented recommendations to clients improving internal control procedures and overall financial policies and procedures• Prepared and drafted financial statements along with proposed footnotes in accordance with GAAP